Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gossamer Bio, Inc. - Common Stock
(NQ:
GOSS
)
0.3781
-0.0419 (-9.98%)
Streaming Delayed Price
Updated: 3:52 PM EDT, Apr 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gossamer Bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
The trading volume of these stocks is deviating from the norm in today's session.
↗
February 25, 2026
Via
Chartmill
In today's session, these stocks are experiencing unusual volume.
↗
February 24, 2026
Via
Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
↗
February 23, 2026
Via
Chartmill
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?
↗
February 23, 2026
Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial.
Via
Stocktwits
These stocks are gapping in today's session
↗
February 23, 2026
Via
Chartmill
Exploring Gossamer Bio's Earnings Expectations
↗
May 14, 2025
Via
Benzinga
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
February 23, 2026
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2026
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Participate in Upcoming Investor Conferences
November 24, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Participate in Upcoming Investor Conferences
November 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
November 05, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
September 25, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
September 22, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
This Saia Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
↗
September 10, 2025
Via
Benzinga
Gossamer Bio to Present at Upcoming Investor Conferences
August 29, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
August 05, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
July 14, 2025
Via
Benzinga
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
June 16, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
↗
June 13, 2025
Via
Stocktwits
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
May 15, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
May 12, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Earnings Scheduled For May 15, 2025
↗
May 15, 2025
Via
Benzinga
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
May 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
